Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 25;10:1527. doi: 10.3389/fonc.2020.01527

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Li, Huang, Zhang, Feng, Wang, Tang, Zhong, Hu, Guo, Zhou, Guo, Xu, Yang and Tong.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Antitumor activity by B7-H3 × CD3 BiAb in combination with trametinib in vivo. (A) Experiment design scheme. (B,C) Tumor growth curves from H460 (B) and T24 (C) mice models treated with T cell, T cell with trametinib, the BiAb or the BiAb combined with trametinib. Tumor volume measurements were recorded every 3 days. (D,E) Tumors from H460 (D) and T24 (E) mice models on day 21 are shown. (F) H&E staining images of liver, spleen, kidney, heart, and lung in H460 mice models. (G,H) Bodyweight of H460 (G) and T24 (H) mice treated with T cell, T cell with trametinib, the BiAb or the BiAb combined with trametinib. Bodyweight measurements were recorded every 3 days.